Literature DB >> 36176652

Balancing Hyperkalemia Risks with Clinical Benefits of Renin-Angiotensin-Aldosterone Inhibitors/Mineralocorticoid Receptor Antagonists Blockade: It's Apples and Oranges.

Silvia J Leon1, Navdeep Tangri2.   

Abstract

Entities:  

Keywords:  ACE inhibitors; ARB; MRA; RAAS inhibitor; chronic kidney disease; finerenone; hyperkalemia; potassium binders

Mesh：

Substances：

Year:  2022        PMID： 36176652      PMCID： PMC9416839          DOI： 10.34067/KID.0000952022

Source DB:  PubMed          Journal:  Kidney360        ISSN： 2641-7650


× No keyword cloud information.
  15 in total

Review 1.  Chronic kidney disease.

Authors:  Andrew S Levey; Josef Coresh
Journal:  Lancet       Date:  2011-08-15       Impact factor: 79.321

Review 2.  New therapies for hyperkalemia.

Authors:  Silvia J Leon; Oksana Harasemiw; Navdeep Tangri
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-05       Impact factor: 2.894

3.  Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

Authors:  Catherine M Clase; Juan-Jesus Carrero; David H Ellison; Morgan E Grams; Brenda R Hemmelgarn; Meg J Jardine; Csaba P Kovesdy; Gregory A Kline; Gregor Lindner; Gregorio T Obrador; Biff F Palmer; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Roberto Pecoits-Filho
Journal:  Kidney Int       Date:  2019-10-10       Impact factor: 10.612

Review 4.  Aldosterone antagonists for preventing the progression of chronic kidney disease.

Authors:  Davide Bolignano; Suetonia C Palmer; Sankar D Navaneethan; Giovanni F M Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2014-04-29

5.  Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data.

Authors:  T H Jafar; C H Schmid; M Landa; I Giatras; R Toto; G Remuzzi; G Maschio; B M Brenner; A Kamper; P Zucchelli; G Becker; A Himmelmann; K Bannister; P Landais; S Shahinfar; P E de Jong; D de Zeeuw; J Lau; A S Levey
Journal:  Ann Intern Med       Date:  2001-07-17       Impact factor: 25.391

Review 6.  Potassium homeostasis and renin-angiotensin-aldosterone system inhibitors.

Authors:  Matthew R Weir; Mark Rolfe
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-11       Impact factor: 8.237

7.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.

Authors:  Paul A Heidenreich; Biykem Bozkurt; David Aguilar; Larry A Allen; Joni J Byun; Monica M Colvin; Anita Deswal; Mark H Drazner; Shannon M Dunlay; Linda R Evers; James C Fang; Savitri E Fedson; Gregg C Fonarow; Salim S Hayek; Adrian F Hernandez; Prateeti Khazanie; Michelle M Kittleson; Christopher S Lee; Mark S Link; Carmelo A Milano; Lorraine C Nnacheta; Alexander T Sandhu; Lynne Warner Stevenson; Orly Vardeny; Amanda R Vest; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2022-04-01       Impact factor: 24.094

8.  Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials.

Authors:  Brendon L Neuen; Megumi Oshima; Rajiv Agarwal; Clare Arnott; David Z Cherney; Robert Edwards; Anna Maria Langkilde; Kenneth W Mahaffey; Darren K McGuire; Bruce Neal; Vlado Perkovic; Annpey Pong; Marc S Sabatine; Itamar Raz; Tadashi Toyama; Christoph Wanner; David C Wheeler; Stephen D Wiviott; Bernard Zinman; Hiddo J L Heerspink
Journal:  Circulation       Date:  2022-04-08       Impact factor: 39.918

9.  Hyperkalemia and its Association With Mortality, Cardiovascular Events, Hospitalizations, and Intensive Care Unit Admissions in a Population-Based Retrospective Cohort.

Authors:  Ingrid Hougen; Silvia J Leon; Reid Whitlock; Claudio Rigatto; Paul Komenda; Clara Bohm; Navdeep Tangri
Journal:  Kidney Int Rep       Date:  2021-03-17

10.  Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.

Authors:  Rajiv Agarwal; Gerasimos Filippatos; Bertram Pitt; Stefan D Anker; Peter Rossing; Amer Joseph; Peter Kolkhof; Christina Nowack; Martin Gebel; Luis M Ruilope; George L Bakris
Journal:  Eur Heart J       Date:  2022-02-10       Impact factor: 35.855
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.